Imaging test for advanced ovarian cancer using a special PET tracer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests a special imaging agent (89Zr-DFO-Mirvetuximab) that may help doctors see ovarian cancer more clearly on PET/CT scans. It is for people with advanced or recurring ovarian cancer to assess if the drug is safe and effective for imaging.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have ovarian cancer that is either newly diagnosed at stage IV or has returned after initial treatment.
- You must have at least one tumor that can be measured on imaging scans.
- Your blood counts, liver, and kidney function must be within acceptable limits.
- You must not be pregnant or breastfeeding, and if you can become pregnant, you must agree to use effective birth control during the study and for 6 months after.
- You must be able to lie still for 30 minutes and not have severe claustrophobia or allergies to the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called mirvetuximab soravtansine (MIRV) for people with ovarian cancer that has a specific protein (FRα). It aims to see how well the drug works in real-world settings, either alone or with other treatments.
This study uses two types of PET/CT scans (68Ga-FAPI-46 and 18F-FDG) to look for any returning ovarian cancer. The goal is to find recurrence early so you and your doctor can plan the next steps.
This trial tests a combination of chemotherapy (carboplatin) and a targeted drug (mirvetuximab soravtansine) given through a vein. It is for people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific protein called folate receptor alpha (FRα) on at least 75% of tumor cells.
This trial tests multiple combinations of the drug mirvetuximab soravtansine with other treatments for people with ovarian cancer. It aims to see how well these combos work and what side effects they cause.
This trial studies how well medical imaging (especially MRI) can help predict outcomes and improve diagnosis in people newly diagnosed with certain gynecologic cancers. It may help doctors make more accurate treatment decisions by comparing imaging results to the final cancer type and stage.
This Phase 2 study tests adding mirvetuximab to carboplatin for people with advanced, high-grade serous ovarian cancer who will first receive “neoadjuvant” chemotherapy. It is designed for tumors that strongly show FRα, which mirvetuximab targets, to see if this improves outcomes.
Hear when a new Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.